The Assessment of the Clinical Effect of the Drug Compatibility and Course of Treatment to the Brucellar Spondylitis


Objective: To evaluate five drug treatment regimens in the treatment of Brucella spondylitis. Methods: Patients with clinical symptoms compatible and diagnostic test consistent with Brucella spondylitis were randomly assigned to five drug treatment regimens. Results: Combination therapy with doxycycline, rifampin and sulfamethoxazole for 56 consecutive days showed the highest cure rate of 20% after a single course and of 85% after a double course with affectivity rates of 55% and 95%. Cure rate and affectivity rate was significant better (P < 0.05) than for patients receiving doxycycline, rifampin and streptomycin for the same period and regimens containing doxycycline were significant better than regimens without this drug. Conclusion: Combination therapy of doxycycline, rifampin and sulfamethoxazole for 8 weeks using one or two full courses should be recommended for Brucella spondylitis.

Share and Cite:

Yang, X. , Shi, W. , Meng, X. , Zhang, Y. , Du, Y. , Zhang, L. and Wang, Y. (2013) The Assessment of the Clinical Effect of the Drug Compatibility and Course of Treatment to the Brucellar Spondylitis. Surgical Science, 4, 92-99. doi: 10.4236/ss.2013.41017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. Turgut, A. T. Turgut and U. Kosar, “Spinal Brucellosis: Turkish Experience Based on 452 Cases Published during the Last Century,” Acta Neurochirgica, Vol. 148, No. 10, 2006, pp. 1033-1044. doi:10.1007/s00701-006-0877-3
[2] A. Raptopoulou, A. H. Karantanas, K. Poumboulidis, G. Grollios, M. Raptopoulou-Gigi and A. Garyfallos, “Brucellar Spondylodiscitis: Noncontiguous Multifocal Involvement of the Cervical, Thoracic, and Lumbar Spine,” Clinical Imaging, Vol. 30, No. 3, 2006, pp. 214-217. doi:10.1016/j.clinimag. 2005.10.006
[3] M. H. Yilmaz, B. Mete, F. Kantarci, R. Ozaras, H. Ozer, A. Mert, I. Mihmanli, R. Ozturk and K. Kanbergoglu, “Tuberculous, Brucellar and Pyogenic Spondylitis: Comparison of Magnetic Resonance Imaging Findings and Assessment of Its Value,” South Medical Journal, Vol. 100, No. 6, 2007, pp. 613-614. doi:10.1097/SMJ.0b013e3180600eaa
[4] J. S. G. del Pozo, M. V. Soto and J. Solera, “Vertebral Osteomyelitis: Long-Term Disability Assessment and Prognostic Factors,” Journal of Infection, Vol. 54, No. 2, 2007, pp. 129-134. doi:10.1016/j.jinf.2006.01.013
[5] P. Atonis, M. Tzermiadianos, A. Gikas, P. Papagelopoulos and A. Hadjipavlou, “Surgical Treatment of Spinal Brucellosis,” Clinical Orthopaedics & Related Research, Vol. 444, 2006, pp. 66-72. doi:10.1097/01.blo.0000203455.59393.9a
[6] J. S. G. del. Pozo, M. V. Soto, M. Lizan-Garcia, E. Martinez-Alfaro, J. C. Segura-Luque and J. Solera-Santos, “Incidence of Infectious Spondylitis in the Province of Albacete (Spain),” Enfermedades Infecciosas y Microbiología Clínica, Vol. 23, No. 9, 2005, pp. 545-550. doi:10.1157/13080265
[7] E. T. Tali, “Spinal Infections,” European Journal of Radiology, Vol. 50, No. 2, 2004, pp. 120-133. doi:10.1016/j.ejrad.2003.10.022
[8] Y. A. Gokhale, A. G. Ambardekar, A. Bhasin, M. Patil, A. Tillu and J. Kamath, “Brucella Spondylitis and Sacroiliitis in the General Population in Mumbai,” Journal of the Association of Physicians of India, Vol. 51, 2003, pp. 659-666.
[9] X.-M. Yang, W. Shi and Y.-K. Du, “The Clinical Characteristics and Surgical Treatment of Brucellar Spondylitis,” Chinese Journal of Orthopedics, Vol. 28, 2008, pp. 35-40.
[10] X.-M. Yang, W. Shi and Y.-K. Du, “Image Manifestations and Surgical Treatment of Spondylitis Caused by Brucells Infection,” Chinese Journal of Zoonoses, Vol. 23, 2007, pp. 1055-1058.
[11] X.-M. Yang, W. Shi and Y.-K. Du, “Investigation on the Curative of Brucellar Spondylitis,” Chinese Journal of Epidemiology, Vol. 27, 2008, pp. 699-703.
[12] J. M. C. Romero, J. L. R. Salado and F. G. de la Llana, “Differences between Tuberculous Spondylitis and Brucellar Spondylitis,” Anales de Medicina Interna, Vol. 18, No. 6, 2001, pp. 309-311.
[13] D. Ozol, A. Koktener and M. E. Uyar, “Active Pulmonary Tuberculosis with Vertebra and Rib Involvement: Case Report,” South Medical Journal, Vol. 99, No. 2, 2006, pp. 171-173. doi:10.1097/01.smj.0000198642.28149.94
[14] G. Aydin, A. Tosun, I. Keles, E. Ayaslioglu, O. Tosun and S. Orkun, “Brucellar Spondylodiscitis: A Case Report,” International Journal of Clinical Practice, Vol. 60, No. 11, 2006, pp. 1502-1505. doi:10.1111/j.1742-1241.2005.00656.x
[15] K. Z. Yuksel, M. Senoglu, M. Yuksel and M. Gul, “Brucellar Spondylo-Discitis with Rapidly Progressive Spinal Epidural Abscess Presenting with Sciatica,” Spinal Cord, Vol. 44, 2006, pp. 805-808. doi:10.1038/
[16] G. S. Guven, B. Cakir, G. Oz, M. D. Tanriover, E. Turkmen and T. Sozen, “Could Remembering the Prozone Phenomenon Shorten our Diagnostic Journey in Brucellosis?” Rheumatology International, Vol. 26, No. 10, 2006, pp. 933-935. doi:10.1007/s00296-006-0118-3
[17] G. Pappas, S. Seitaridis, N. Akritidis and E. Tsianos, “Treatment of Brucella Spondylitis: Lessons from an Impossible Meta-Analysis and Initial Report of Efficacy of a Fluoroquinolone-Containing Regimen,” International Journal of Antimicrobial Agents, Vol. 24, No. 5, 2004, pp. 502-507. doi:10.1016/j.ijantimicag.2004.05.003
[18] Y. Bayindir, E. Sonmez, A. Aladag and N. Buyukberber, “Comparison of Five Antimicrobial Regimens for the Treatment of Brucellar Spondylitis: A Prospective, Randomized Study,” Journal of Chemotherapy, Vol. 15, No. 5, 2003, pp. 466-471.
[19] J. Solera, P. Geijo and J. Largo, “Arandomized, Double-Blind Study to Assess the Optimal Duration of Doxycycline Treatment for Human Brucellosis,” Clinical Infectious Diseases, Vol. 39, No. 12, 2004, pp. 1776-1782. doi:10.1086/426024
[20] E. Alp, R. K. Koc, A. C. Durak, O. Yildiz, B. Aygen, B. Sumerkan and M. Doganay, “Doxycycline plus Streptomycin versus Ciprofloxacin plus Rifampicin in Spinal Brucellosis,” BMC Infectious Diseases, Vol. 6, 2006, pp. 72-78. doi:10.1186/1471-2334-6-72
[21] N. G. David, C. M. Robert, M. E. George and A. S. Merle, “The Sanford Guided to Antimicrobial Therapy,” 34th Edition, Antimicrobial Theraphy, Inc., Hyde Park, 2004, pp. 48-51.
[22] Y. Bayindir, E. Sonmez, A. Aladag and N. Buyukberber, “Comparison of Five Antimicrobial Regimens for the Treatment of Brucellar Spondylitis: A Prospective, Randomized Study,” Journal of Chemotherapy, Vol. 15, No. 15, 2003, pp. 466-471.
[23] N. Saltoglu, Y. Tasova and A. S. Inal, “Efficacy of Rifampicin plus Doxycycline versus Rifampicin plus Quinolone in the Treatment of Brucellosis,” Saudi Medical Journal, Vol. 23, No. 8, 2002, pp. 921-924.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.